Axogen Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	3.8yrs

Recente managementupdates

Recent updates

Even With A 28% Surge, Cautious Investors Are Not Rewarding AxoGen, Inc.'s (NASDAQ:AXGN) Performance Completely

Sep 14

Would AxoGen (NASDAQ:AXGN) Be Better Off With Less Debt?

Aug 20

A Piece Of The Puzzle Missing From AxoGen, Inc.'s (NASDAQ:AXGN) 28% Share Price Climb

Jul 29

Market Might Still Lack Some Conviction On AxoGen, Inc. (NASDAQ:AXGN) Even After 27% Share Price Boost

Jun 12

Is AxoGen (NASDAQ:AXGN) Using Too Much Debt?

Apr 16

Positive Sentiment Still Eludes AxoGen, Inc. (NASDAQ:AXGN) Following 26% Share Price Slump

Mar 28

Market Might Still Lack Some Conviction On AxoGen, Inc. (NASDAQ:AXGN) Even After 33% Share Price Boost

Jan 26

CEO

Axogen heeft geen CEO, of we hebben geen gegevens over hen.

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Nir Naor	Chief Financial Officer	less than a year	US$509.68k	geen gegevens
Karen Zaderej	Advisor	less than a year	US$5.53m	2.6% $ 15.3m
Erick DeVinney	Chief Innovation Officer	less than a year	US$1.51m	0.30% $ 1.7m
Todd Puckett	Vice President of Operations	less than a year	geen gegevens	geen gegevens
Harold Tamayo	Vice President of Finance & Investor Relations	no data	geen gegevens	geen gegevens
Marc Began	Executive VP	1.7yrs	geen gegevens	geen gegevens
Doris Quackenbush	Vice President of Sales	2.8yrs	geen gegevens	geen gegevens
Jens Kemp	Chief Marketing Officer	1.8yrs	geen gegevens	geen gegevens
Ivica Ducic	Chief Medical Officer	less than a year	geen gegevens	geen gegevens

0.9yrs

Gemiddelde duur

52.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van AXGN wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.9 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Paul Thomas	Independent Director	4.2yrs	US$220.00k	0.049% $ 285.4k
Guido Neels	Independent Director	9.3yrs	US$217.50k	0.18% $ 1.1m
Bruce Mast	Member of Board of Advisor	no data	geen gegevens	geen gegevens
David Muir	Member of Board of Advisor	no data	geen gegevens	geen gegevens
John Johnson	Independent Director	3.3yrs	US$215.00k	0.042% $ 245.0k
Kathy Weiler	Independent Director	less than a year	US$293.37k	geen gegevens
Alan Levine	Independent Director	5.5yrs	US$217.50k	0.069% $ 402.4k
Amy Wendell	Independent Lead Director	8.2yrs	US$255.00k	0.18% $ 1.1m
William Burke	Independent Director	2.3yrs	US$220.00k	0.063% $ 372.3k
Joseph Tyndall	Independent Director	1.9yrs	US$205.00k	0.051% $ 300.9k

3.8yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van AXGN wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Axogen Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Chairman notifies of intention to sell stock

Chairman notifies of intention to sell stock

Axogen, Inc. Announces Chief Executive Officer Changes

AxoGen, Inc., Annual General Meeting, Jun 05, 2024

Chairman exercised options and sold US$302k worth of stock

Vice President of Operations recently sold US$320k worth of stock

Recent updates

Consensus EPS estimates upgraded to US$0.30 loss

Price target increased by 8.1% to US$17.83

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Axogen, Inc. Maintains Earnings Guidance for 2024

Forecast breakeven date pushed back to 2026

Axogen, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Even With A 28% Surge, Cautious Investors Are Not Rewarding AxoGen, Inc.'s (NASDAQ:AXGN) Performance Completely

Chairman notifies of intention to sell stock

Would AxoGen (NASDAQ:AXGN) Be Better Off With Less Debt?

Chairman notifies of intention to sell stock

Price target increased by 8.8% to US$14.50

Axogen, Inc. Announces Chief Executive Officer Changes

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

AxoGen, Inc. Updates Earnings Guidance for the Full Year 2024

A Piece Of The Puzzle Missing From AxoGen, Inc.'s (NASDAQ:AXGN) 28% Share Price Climb

AxoGen, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Forecast breakeven date pushed back to 2026

Axogen, Inc. Announces Full Launch of Avive+ Soft Tissue Matrix

Market Might Still Lack Some Conviction On AxoGen, Inc. (NASDAQ:AXGN) Even After 27% Share Price Boost

Forecast breakeven date moved forward to 2025

Axogen, Inc. Provides Revenue Guidance for the Year 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Profitability

Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix

AxoGen, Inc., Annual General Meeting, Jun 05, 2024

AxoGen, Inc. to Report Q1, 2024 Results on May 02, 2024

Is AxoGen (NASDAQ:AXGN) Using Too Much Debt?

New minor risk - Shareholder dilution

Positive Sentiment Still Eludes AxoGen, Inc. (NASDAQ:AXGN) Following 26% Share Price Slump

Chairman exercised options and sold US$302k worth of stock

Consensus EPS estimates fall by 39%

Vice President of Operations recently sold US$320k worth of stock

AxoGen, Inc. Announces Executive Changes

New minor risk - Shareholder dilution

AxoGen, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Third quarter 2023 earnings released: US$0.095 loss per share (vs US$0.10 loss in 3Q 2022)

Forecast breakeven date pushed back to 2026

Market Might Still Lack Some Conviction On AxoGen, Inc. (NASDAQ:AXGN) Even After 33% Share Price Boost

Axogen, Inc. Announces Positive Topline Results from Its REPOSE Clinical Study

Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025

Axogen, Inc. Appoints Kathy Weiler to its Board of Directors

Insider recently sold US$94k worth of stock

AxoGen, Inc. Announces CFO Changes

Forecast to breakeven in 2025

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Axogen, Inc. Provides Revenue Guidance for the Full-Year 2023

AxoGen, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Price target decreased by 13% to US$14.20

We Think AxoGen (NASDAQ:AXGN) Has A Fair Chunk Of Debt

Axogen, Inc. Announces Full Launch of Axoguard HA+ Nerve Protector

Independent Director recently bought US$66k worth of stock

Independent Director recently bought US$61k worth of stock

Axogen, Inc. Provides Revenue Guidance for the Year 2023

Market Cool On AxoGen, Inc.'s (NASDAQ:AXGN) Revenues

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

AxoGen, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Director recently sold US$366k worth of stock

Director notifies of intention to sell stock

Director notifies of intention to sell stock

Director recently sold US$69k worth of stock

AxoGen, Inc. Provides Earnings Guidance for the Full-Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Executive VP & CFO exercised options and sold US$58k worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations

Price target decreased by 8.5% to US$16.25

Axogen, Inc. Appoints Jens Schroeder Kemp as Chief Marketing Officer

Executive VP & CFO exercised options and sold US$318k worth of stock

AxoGen (NASDAQ:AXGN) Has Debt But No Earnings; Should You Worry?